Management of adult patients with Langerhans cell histiocytosis : Recommendations from an expert panel on behalf of Euro-Histio-Net
Girschikofsky, Michael (Elisabethinen Hospital (Linz, Austria))
Arico, Maurizio (Azienda Ospedaliero Universitaria A. Meyer (Florència, Itàlia))
Castillo, Diego (Institut d'Investigació Biomèdica Sant Pau)
Chu, Anthony (Imperial NHS Trust)
Doberauer, Claus (Clinic for Internal Medicine)
Fichter, Joachim (Paracelsus Klinik)
Haroche, Julien (Groupe Hospitalier Pitié-Salpêtrière)
Kaltsas, Gregory A. (University of Athens)
Makras, Polyzois (251 Hellenic Air Force and VA General Hospital (Atenes, Grècia))
Marzano, Angelo V. (Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (Milà, Itàlia))
De Menthon, Mathilde (Hospital Saint Louis (París, França))
Micke, Oliver (Franziskus Hospital)
Passoni, Emanuela (Ospedale Maggiore Policlinico)
Seegenschmiedt, Heinrich M. (Radiation Oncology Center)
Tazi, Abdellatif (Saint Louis Teaching Hospital)
McClain, K.L. (Texas Children's Cancer Center)
Universitat Autònoma de Barcelona

Data:	2013
Resum:	Langerhans Cell Histiocytosis (LCH) is an orphan disease of clonal dendritic cells which may affect any organ of the body. Most of the knowledge about the diagnosis and therapy is based on pedriatic studies. Adult LCH patients are often evaluated by physicians who focus on only the most obviously affected organ without sufficient evaluation of other systems, resulting in patients being underdiagnosed and/or incompletely staged. Furthermore they may be treated with pediatric-based therapies which are less effective and sometimes more toxic for adults. The published literature on adult LCH cases lacks a comprehensive discussion on the differences between pediatric and adult patients and there are no recommendations for evaluation and comparative therapies. In order to fill this void, a number of experts in this field cooperated to develop the first recommendations for management of adult patients with LCH. Key questions were selected according to the clinical relevance focusing on diagnostic work up, therapy, and follow up. Based on the available literature up to December 2012, recommendations were established, drafts were commented by the entire group, and redrafted by the executive editor. The quality of evidence of the recommendations is predominantly attributed to the level of expert opinion. Final agreement was by consensus. © 2013 Girschikofsky et al. ; licensee BioMed Central Ltd.
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article de revisió ; recerca ; Versió publicada
Matèria:	Adult ; Histiocytosis ; Langerhans
Publicat a:	Orphanet journal of rare diseases, Vol. 8 Núm. 1 (2013) , p. 72, ISSN 1750-1172

DOI: 10.1186/1750-1172-8-72
PMID: 23672541

11 p, 334.9 KB

El registre apareix a les col·leccions:
Documents de recerca > Documents dels grups de recerca de la UAB > Centres i grups de recerca (producció científica) > Ciències de la salut i biociències > Institut de Recerca Sant Pau
Articles > Articles de recerca
Articles > Articles publicats